Cargando…

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy

Ulotaront, a trace amine-associated receptor 1 (TAAR1) and serotonin 5-HT1A receptor agonist without antagonist activity at dopamine D(2) or the serotonin 5-HT2A receptors, has demonstrated efficacy in the treatment of schizophrenia. Here we report the phase 1 translational studies that profiled the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perini, Francesca, Nazimek, Jadwiga Maria, Mckie, Shane, Capitão, Liliana P., Scaife, Jessica, Pal, Deepa, Browning, Michael, Dawson, Gerard R., Nishikawa, Hiroyuki, Campbell, Una, Hopkins, Seth C., Loebel, Antony, Elliott, Rebecca, Harmer, Catherine J., Deakin, Bill, Koblan, Kenneth S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406926/ https://www.ncbi.nlm.nih.gov/pubmed/37550314 http://dx.doi.org/10.1038/s41537-023-00385-6

Ejemplares similares

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
por: Correll, Christoph U., et al.
Publicado: (2021)

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
por: Heffernan, Michele L. R., et al.
Publicado: (2021)

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
por: Achtyes, Eric D., et al.
Publicado: (2023)

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS
por: Hopkins, Seth C., et al.
Publicado: (2021)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
por: Chen, Yu-Luan, et al.
Publicado: (2023)

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022)

T109. CLUSTERING OF SCHIZOPHRENIA PATIENT SUBTYPES BY SPECIFIC SYMPTOM DIMENSIONS USING AN UNCORRELATED PANSS SCORE MATRIX (UPSM)
por: Hopkins, Seth, et al.
Publicado: (2018)

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia
por: Hopkins, Seth C, et al.
Publicado: (2018)

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders
por: Hopkins, Seth C., et al.
Publicado: (2021)

A Dissociation of the Acute Effects of Bupropion on Positive Emotional Processing and Reward Processing in Healthy Volunteers
por: Walsh, Annabel E. L., et al.
Publicado: (2018)

Scenario-specific aberrations of social reward processing in dimensional schizotypy and psychopathy
por: Aldridge-Waddon, Luke, et al.
Publicado: (2022)

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia
por: Tsukada, Hironobu, et al.
Publicado: (2023)

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT(1A) Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Neural bases of reward anticipation in healthy individuals with low, mid, and high levels of schizotypy
por: Carruzzo, F., et al.
Publicado: (2023)

Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
por: Hopkins, Seth C., et al.
Publicado: (2015)

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults
por: Koblan, Kenneth S, et al.
Publicado: (2015)

The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers
por: McCabe, Ciara, et al.
Publicado: (2011)

The Emotional Characteristics of Schizotypy
por: Yoon, Seon-Ah, et al.
Publicado: (2008)

Intermittent degradation and schizotypy
por: Roché, Matthew W., et al.
Publicado: (2015)

Positive schizotypy and negative schizotypy are associated with differential patterns of episodic memory impairment
por: Sahakyan, Lili, et al.
Publicado: (2016)

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
por: Kuvarzin, Savelii R., et al.
Publicado: (2023)

The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study
por: De Giorgi, Riccardo, et al.
Publicado: (2021)

Multidimensional schizotypy and embodied emotions
por: Torregrossa, Lénie J., et al.
Publicado: (2023)

An experimental medicine study of the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation in healthy volunteers
por: De Giorgi, Riccardo, et al.
Publicado: (2022)

In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics
por: Ågren, Richard, et al.
Publicado: (2023)

An investigation into aripiprazole’s partial D(2) agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers
por: Murphy, Anna, et al.
Publicado: (2016)

Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies
por: Koychev, I, et al.
Publicado: (2016)

Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study
por: Wigal, Sharon B., et al.
Publicado: (2019)

Sense of agency, associative learning, and schizotypy
por: Moore, James W., et al.
Publicado: (2011)

Schizotypy and Behavioural Adjustment and the Role of Neuroticism
por: Völter, Christoph, et al.
Publicado: (2012)

The Duality of Schizotypy: Is it Both Dimensional and Categorical?
por: Mason, Oliver John
Publicado: (2014)

An Overview of the Association between Schizotypy and Dopamine
por: Mohr, Christine, et al.
Publicado: (2014)

Spatiotemporal processing of somatosensory stimuli in schizotypy
por: Ferri, Francesca, et al.
Publicado: (2016)

Explicit and Implicit Affect and Judgment in Schizotypy
por: Martin, Elizabeth A., et al.
Publicado: (2019)

The network structure of schizotypy in the general population
por: Polner, Bertalan, et al.
Publicado: (2019)

Increased structural connectivity in high schizotypy
por: Messaritaki, Eirini, et al.
Publicado: (2023)

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects
por: Tsukada, Hironobu, et al.
Publicado: (2023)

Multispecies probiotic administration reduces emotional salience and improves mood in subjects with moderate depression: a randomised, double-blind, placebo-controlled study
por: Baião, Rita, et al.
Publicado: (2023)

The Silent Side of the Spectrum: Schizotypy and the Schizotaxic Self
por: Raballo, Andrea, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_q95kd8jml8kfnsbigb8k8lq54h